By Alexa Heah, 09 Mar 2022
92 low- and middle-income countries can use the company’s vaccine data.
Moderna has announced it will “never enforce” its patents for its mRNA COVID-19 vaccines in 92 low- and middle-income countries under the Gavi COVAX Advance Market Commitment.
“We are committed to defeating the pandemic across the globe, and we are fulfilling that through our pledge not to enforce our COVID-19 related patents in low- and middle-income countries,” said Moderna CEO Stéphane Bancel.
“We are dedicated to combatting COVID-19 globally and preparing for the next pandemic,” she added.
Alongside with this initiative, Moderna will also be partnering with the government of Kenya to build an mRNA manufacturing facility, in hopes of producing up to 500 million doses annually.
Reuters reported that it plans to start production of the COVID-19 vaccine in Africa as early as next year. […]